[go: up one dir, main page]

WO1999029865A3 - Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation - Google Patents

Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation Download PDF

Info

Publication number
WO1999029865A3
WO1999029865A3 PCT/US1998/026486 US9826486W WO9929865A3 WO 1999029865 A3 WO1999029865 A3 WO 1999029865A3 US 9826486 W US9826486 W US 9826486W WO 9929865 A3 WO9929865 A3 WO 9929865A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
vivo
animal
dendritic cells
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/026486
Other languages
English (en)
Other versions
WO1999029865A9 (fr
WO1999029865A2 (fr
Inventor
Youngwon Choi
Brian Won
Regis Josien
Ralph Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of WO1999029865A2 publication Critical patent/WO1999029865A2/fr
Publication of WO1999029865A9 publication Critical patent/WO1999029865A9/fr
Publication of WO1999029865A3 publication Critical patent/WO1999029865A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode de modulation d'une réponse immunitaire chez un animal. Cette méthode permet de mettre en interaction les cellules dendritiques immatures de l'animal avec un antigène ex vivo de sorte que les cellules dendritiques immatures présentent l'antigène à leur surface; de provoquer la maturation des cellules dendritiques immatures ex vivo; et de mettre en contact les cellules dendritiques matures ex vivo avec un modulateur comprenant une protéine TRANCE (cytokine induite par activation liée à un TNF), ses variants conservateurs, ses fragments, ses analogues ou dérivés, ou une protéine de fusion comprenant la séquence d'acides aminés de la protéine TRANCE, ses variants conservateurs ou ses fragments. Après leur mise en contact avec le modulateur ex vivo, on introduit les cellules dendritiques matures dans l'animal. Par conséquent, la réponse immunitaire chez l'animal à l'antigène est modulée par rapport à la réponse immunitaire contre l'antigène pour un animal chez lequel il n'y a pas eu d'interaction des cellules dendritiques avec l'antigène ex vivo, et les cellules dendritiques n'ont pas été en contact avec un modulateur ex vivo. De préférence, la méthode selon la présente invention permet d'augmenter la réponse immunitaire à l'antigène chez l'animal.
PCT/US1998/026486 1997-12-12 1998-12-14 Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation Ceased WO1999029865A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98947997A 1997-12-12 1997-12-12
US08/989,479 1997-12-12
US3409998A 1998-03-03 1998-03-03
US09/034,099 1998-03-03

Publications (3)

Publication Number Publication Date
WO1999029865A2 WO1999029865A2 (fr) 1999-06-17
WO1999029865A9 WO1999029865A9 (fr) 1999-11-04
WO1999029865A3 true WO1999029865A3 (fr) 1999-12-16

Family

ID=26710553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026486 Ceased WO1999029865A2 (fr) 1997-12-12 1998-12-14 Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation

Country Status (1)

Country Link
WO (1) WO1999029865A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE517916T1 (de) 1998-05-14 2011-08-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2001072703A1 (fr) 2000-03-24 2001-10-04 Pharmacia Corporation Compose amidino et sels de ce dernier utiles comme inhibiteurs de l'oxyde nitrique synthase
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US6956131B2 (en) 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
WO2002016551A2 (fr) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Regulation par trance de la differenciation des chondrocytes
US20030211106A1 (en) * 2000-08-21 2003-11-13 Tornetta Mark A Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6884598B2 (en) 2000-09-22 2005-04-26 Immunex Corporation Screening assays for agonists and antagonists of receptor activator of NF-κB
AU2002241859B2 (en) 2001-01-10 2007-07-19 St. Vincent's Institute Of Medical Research sFRP and peptide motifs that interact with sFRP and methods of their use
JP2005508284A (ja) * 2001-03-23 2005-03-31 ジェネンテック・インコーポレーテッド 免疫反応調節のためのｏｐｇリガンドの使用
TR201900581T4 (tr) 2001-06-26 2019-02-21 Amgen Fremont Inc Opgl ye karşı antikorlar.
WO2005028633A2 (fr) 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation de l'expression du rankl
WO2008043157A1 (fr) 2006-10-12 2008-04-17 The University Of Queensland Compositions et procédés destinés à moduler des réponses immunes
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (fr) * 1996-12-23 1998-07-02 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (fr) * 1996-12-23 1998-07-02 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDERSON D.M. ET AL.: "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", NATURE, vol. 390, no. 6656, 13 November 1997 (1997-11-13), us, pages 175 - 179, XP002107475 *
LACEY D.L. ET AL.: "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", CELL, vol. 93, no. 2, 17 April 1998 (1998-04-17), pages 165 - 176, XP002117567 *
WONG B R ET AL: "TRANCE is a novel ligand of the Tumor Necrosis Factor Receptor Family that activates c-Jun-terminal kinase in T cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 40, 3 October 1997 (1997-10-03), pages 25190 - 25194, XP002065547 *
WONG B.R. ET AL.: "The TRAF family of signal transducers mediates NF-kB Aktivation by the TRANCE receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 43, 23 October 1998 (1998-10-23), US, pages 28355 - 28359, XP002107477 *
WONG B.R. ET AL.: "TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced cytokine), a TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 12, 15 December 1997 (1997-12-15), US, XP002107476 *
YASUDA H ET AL: "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis -inhibitory factor and is identical to TRANCE/RANKL", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, no. 95, 31 March 1998 (1998-03-31), pages 3597 3602, XP002076248 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein

Also Published As

Publication number Publication date
WO1999029865A9 (fr) 1999-11-04
WO1999029865A2 (fr) 1999-06-17

Similar Documents

Publication Publication Date Title
WO1999029865A3 (fr) Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
ATE291628T1 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
WO1996040945A3 (fr) Vaccins a acides nucleiques du virus respiratoire syncytial
EP1847549A3 (fr) Constructions de polyprotéine de papillomavirus
NZ504936A (en) Simultaneous administration of polynucleotide and delayed release polypeptide encoded by the polynucleotide to enhance an immune response of nucleic acid vaccination
WO2002005146A3 (fr) Automatisation de conception de proteines pour la conception de bibliotheques de proteines a antigenicite modifiee
CA2231603A1 (fr) Interleukine-15 du poulet et ses utilisations
WO2000034317A3 (fr) Modification de l'immunogenicite de proteines
WO2002016418A3 (fr) Peptide ou polypeptide capable de liaison avec l'inhibiteur de la proteine de l'apoptose
GR3033094T3 (en) Methods for trans-destabilization of specific proteins in vivo.
CA2169297A1 (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
WO1998024888A3 (fr) Polypeptides llg de la famille des triacylglycerol lipases, compositions et procedes destines a l'utilisation de ceux-ci dans des hydrolyses enzymatiques, et therapies geniques et protidiques
WO2002029057A3 (fr) 32144, nouveau membre de la famille des amides hydrolases d'acide gras humaines
DE69734644D1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
DE69626522D1 (de) Peptide mit pronociceptiveigenschaften
CA2176236A1 (fr) Enzyme de fusion de la proteine activatrice de la tyrosinase
WO1996004011A3 (fr) Nouveau compose simulant un effet peptidique naturel
WO2001092493A3 (fr) Nouvelles aminopeptidases humaines 21956 et 25856, et utilisations
WO2003012121A3 (fr) Nouveau collagene d'origine humaine, dit collagene xxii, et ses utilisations
WO2001075076A3 (fr) 33167, nouvelle hydrolase humaine, et utilisations associees
WO2001067097A3 (fr) Nouveau procede d'analyse biologique
WO2002026958A3 (fr) Nouvelle neprilysine protease humaine denommee 56638, et utilisations associees
WO1997035997A3 (fr) Poxvirus recombinant codant pour la proteine de la myeline et destine a un usage therapeutique
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
WO2001096542A3 (fr) 23680, nouvelle aminotransferase humaine et utilisations de celle-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/26-26/26, DRAWINGS, REPLACED BY NEW PAGES 1/40-40/40; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase